Protagonist drug hits goals in pivotal study of rare blood cancer

An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a rare blood cancer — achieving the efficacy goals of a Phase 3 study.

Based on the positive study results, announced Monday, Protagonist and its partner Takeda will submit the drug, called rusfertide, for approval in the U.S. and Europe later this year. The companies are developing the drug as a new treatment for polycythemia vera, a type of blood cancer that causes the overproduction of red blood cells.

Shares of Protagonist were up 9% to $39.44 in early Monday trading.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Ceftriaxone Prevents Ventilator-Associated Pneumonia After Brain Injury

PHOENIX — Administering ceftriaxone prophylactically in the intensive care unit (ICU) reduced the risk of ventilator-associated pneumonia (VAP) among patients with an acute brain injury,

January 23, 2024

Emerging Biotech Breakthroughs: Promising Stocks in Medical Innovation

From breakthrough technologies to pioneering companies, biotech stocks offer investors a glimpse into the future of medicine.

June 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.